Efficacy of Pregabalin on Chronic Cough

NCT ID: NCT02482818

Last Updated: 2020-09-25

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2021-12-31

Brief Summary

The purpose of this study is to determine if Pregabalin, a medication used for the treatment of seizures and chronic pain, can be used to effectively treat people who suffer from non-asthmatic chronic cough (cough lasting over 8 weeks).

Detailed Description

A significant number of patients have an impaired quality of life due to chronic cough that fails to respond to therapeutic efforts.

Research suggests that patients with chronic cough may have an oversensitive cough reflex. Reflexes are involuntary responses to nerve stimulation. Since standard cough medicines may not be helpful for treating the oversensitive cough reflex, treatment with neurologically acting agents has been investigated.

Existing work in treatment of cough of unknown etiology has focused on the use of Gabapentin, a compound that acts neurologically that is used in the treatment of epilepsy and pain. A similar drug, Pregabalin, may be a superior medication for this indication. Pregabalin is rapidly absorbed with peak blood concentrations within 1 hour, has an approximate bioavailability of 90%, and is 3 to 10 times more potent than Gabapentin and has no known pharmacokinetic drug interactions.

Conditions

Cough

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Control-Placebo

Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.

Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).

Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.

Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42.

Group Type: PLACEBO_COMPARATOR

Control-Placebo

Intervention Type: DRUG

A control substance, Lactose is administered in place of Pregabalin.

Pregabalin

Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.

Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).

Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.

Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.

Forty two days after initial drug administration the Doctor will meet with subjects to follow up.

Group Type: EXPERIMENTAL

Pregabalin

Intervention Type: DRUG

Increasing dose regimen depending on tolerability followed by decreasing dose regimen.

Interventions

Pregabalin

Increasing dose regimen depending on tolerability followed by decreasing dose regimen.

Intervention Type: DRUG

Control-Placebo

A control substance, Lactose is administered in place of Pregabalin.

Intervention Type: DRUG

Other Intervention Names

Lactose Pills.

Eligibility Criteria

Inclusion Criteria

• Diagnosis of non-asthmatic chronic cough defined as a cough experienced for a period of at least 8 weeks
• Negative methacholine challenge (within past year)
• Chest x-ray with absence of gross abnormality that could justify the cough or be a cause for the cough (within past 6 months)
• Male or female 18 years or older
• Willing and able to limit to 1 or less alcohol beverage per day (example: 360 ml of beer or 330 ml of cooler or 120 ml of wine)

• Creatinine clearance < 60ml/min within past three months
• Current Smoker or has been quit less than 8 weeks
• Symptoms of post nasal drip
• History of gastroesophageal reflux. Only participants with untreated Gastroesophageal Reflux Disease (GERD) or less than 8 weeks of therapy will be excluded.
• Symptoms of upper airway cough syndrome
• ACE inhibitor use
• Allergy to citric acid
• Pregnant or nursing women
• History of angioedema or congestive heart failure

Exclusion Criteria

• Concurrent use of Gabapentin or Pregabalin for other indications (seizure disorder, chronic pain)
• History of allergy / intolerance or adverse effect with Gabapentin or Pregabalin.
• Concurrent use of central nervous system depressants (i.e. opioids or benzodiazepines)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 84 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ottawa Hospital Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kayvan Amjadi, MD

Role: PRINCIPAL_INVESTIGATOR

Ottawa Hospital Research Institute

Locations

The Ottawa Hospital (General and Civic Campuses)

Ottawa, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Kayvan Amjadi, MD

Role: CONTACT

kamjadi@toh.on.ca

613-798-5555 ext. 18139

Nha Voduc, MD

Role: CONTACT

nvoduc@toh.on.ca

613-737-8899 ext. 78198

Facility Contacts

Isabelle Seguin

Role: primary

iseguin@ohri.ca

613-737-8811

Other Identifiers

2011734-01H

Identifier Type: -

Identifier Source: org_study_id